JP7708772B2 - エストロゲン受容体関連疾患の治療方法 - Google Patents

エストロゲン受容体関連疾患の治療方法

Info

Publication number
JP7708772B2
JP7708772B2 JP2022551377A JP2022551377A JP7708772B2 JP 7708772 B2 JP7708772 B2 JP 7708772B2 JP 2022551377 A JP2022551377 A JP 2022551377A JP 2022551377 A JP2022551377 A JP 2022551377A JP 7708772 B2 JP7708772 B2 JP 7708772B2
Authority
JP
Japan
Prior art keywords
estrogen receptor
compound
subject
pharmaceutical composition
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022551377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516291A (ja
JP2023516291A5 (https=
Inventor
サイラス エル． ハーモン，
ピーター ジェイ． クシュナー，
デイビッド シー． マイルス，
レスリー ホッジズ ギャラガー，
Original Assignee
オレマ ファーマシューティカルズ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オレマ ファーマシューティカルズ インク． filed Critical オレマ ファーマシューティカルズ インク．
Publication of JP2023516291A publication Critical patent/JP2023516291A/ja
Publication of JP2023516291A5 publication Critical patent/JP2023516291A5/ja
Priority to JP2025090731A priority Critical patent/JP2025131656A/ja
Application granted granted Critical
Publication of JP7708772B2 publication Critical patent/JP7708772B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022551377A 2020-03-06 2021-03-05 エストロゲン受容体関連疾患の治療方法 Active JP7708772B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025090731A JP2025131656A (ja) 2020-03-06 2025-05-30 エストロゲン受容体関連疾患の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985929P 2020-03-06 2020-03-06
US62/985,929 2020-03-06
PCT/US2021/021151 WO2021178846A1 (en) 2020-03-06 2021-03-05 Methods of treating estrogen receptor-associated diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025090731A Division JP2025131656A (ja) 2020-03-06 2025-05-30 エストロゲン受容体関連疾患の治療方法

Publications (3)

Publication Number Publication Date
JP2023516291A JP2023516291A (ja) 2023-04-19
JP2023516291A5 JP2023516291A5 (https=) 2024-03-14
JP7708772B2 true JP7708772B2 (ja) 2025-07-15

Family

ID=77613854

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022551377A Active JP7708772B2 (ja) 2020-03-06 2021-03-05 エストロゲン受容体関連疾患の治療方法
JP2025090731A Pending JP2025131656A (ja) 2020-03-06 2025-05-30 エストロゲン受容体関連疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025090731A Pending JP2025131656A (ja) 2020-03-06 2025-05-30 エストロゲン受容体関連疾患の治療方法

Country Status (10)

Country Link
US (1) US20230129598A1 (https=)
EP (1) EP4114391B1 (https=)
JP (2) JP7708772B2 (https=)
KR (1) KR20220151616A (https=)
CN (1) CN115175679A (https=)
AU (1) AU2021230588A1 (https=)
CA (1) CA3169679A1 (https=)
ES (1) ES3044433T3 (https=)
MX (1) MX2022010425A (https=)
WO (1) WO2021178846A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003440A2 (pt) 2018-09-07 2021-05-18 Sanofi sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação
KR20220034129A (ko) * 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법
EP4037768B1 (en) 2019-10-01 2023-10-11 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
AU2020399168A1 (en) 2019-12-09 2022-07-28 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) * 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
TW202233572A (zh) 2020-10-19 2022-09-01 法商賽諾菲公司 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
TWI808648B (zh) * 2021-02-16 2023-07-11 美商建南德克公司 使用包含gdc-9545及gdc-0077之組合療法治療乳癌
TW202304424A (zh) * 2021-04-12 2023-02-01 法商賽諾菲公司 包含依維莫司和安森司群的組合
TW202304425A (zh) * 2021-04-12 2023-02-01 法商賽諾菲公司 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
TW202333704A (zh) * 2021-11-12 2023-09-01 大陸商先聲藥業有限公司 用於治療腫瘤的藥物組合及其應用
CA3243621A1 (en) * 2022-02-01 2023-08-10 Eli Lilly And Company METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS
US12330304B2 (en) * 2022-02-02 2025-06-17 Intrinsic Innovation Llc Object placement
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2024015506A1 (en) * 2022-07-14 2024-01-18 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
CN114933558B (zh) * 2022-07-26 2022-11-22 常熟药明康德新药开发有限公司 手性硝基化合物催化还原制备手性氨基化合物的方法
JP2025533900A (ja) * 2022-10-05 2025-10-09 オレマ ファーマシューティカルズ， インコーポレイテッド エストロゲン受容体媒介性障害を治療する方法
WO2024076633A1 (en) * 2022-10-05 2024-04-11 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
CN115872996B (zh) * 2023-02-21 2023-05-05 山东绿叶制药有限公司 一种雌激素受体降解剂化合物及其制备方法和应用
WO2025106890A1 (en) * 2023-11-17 2025-05-22 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138659A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
WO2015149045A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
JP2018514549A (ja) 2015-04-29 2018-06-07 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
WO2018157000A1 (en) 2017-02-23 2018-08-30 Olema Pharmaceuticals, Inc. Compositions and methods for regulating immune system activity
JP2018530549A (ja) 2015-10-01 2018-10-18 オレマ ファーマシューティカルズ インク． テトラヒドロ−１Ｈ−ピリド［３，４−ｂ］インドール抗エストロゲン薬物
WO2020023297A1 (en) 2018-07-23 2020-01-30 Genentech, Inc. Methods of treating cancer with pi3k inhibitor, gdc-0077

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2819299A1 (en) 2010-12-24 2012-06-28 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
EP2791128A4 (en) 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
UY35590A (es) 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
SG11201607339VA (en) * 2014-03-13 2016-10-28 Hoffmann La Roche Methods and compositions for modulating estrogen receptor mutants
TWI874834B (zh) * 2014-12-18 2025-03-01 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
CR20200621A (es) 2018-06-21 2021-02-03 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
JP7571006B2 (ja) * 2018-08-17 2024-10-22 ジェネンテック， インコーポレイテッド 乳がんの処置のための診断的および治療的方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138659A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
WO2015149045A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
JP2018514549A (ja) 2015-04-29 2018-06-07 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
JP2018530549A (ja) 2015-10-01 2018-10-18 オレマ ファーマシューティカルズ インク． テトラヒドロ−１Ｈ−ピリド［３，４−ｂ］インドール抗エストロゲン薬物
WO2018157000A1 (en) 2017-02-23 2018-08-30 Olema Pharmaceuticals, Inc. Compositions and methods for regulating immune system activity
WO2020023297A1 (en) 2018-07-23 2020-01-30 Genentech, Inc. Methods of treating cancer with pi3k inhibitor, gdc-0077

Also Published As

Publication number Publication date
EP4114391B1 (en) 2025-07-09
JP2023516291A (ja) 2023-04-19
AU2021230588A1 (en) 2022-08-25
MX2022010425A (es) 2022-09-07
KR20220151616A (ko) 2022-11-15
US20230129598A1 (en) 2023-04-27
JP2025131656A (ja) 2025-09-09
CN115175679A (zh) 2022-10-11
EP4114391A1 (en) 2023-01-11
WO2021178846A1 (en) 2021-09-10
EP4114391A4 (en) 2024-05-22
CA3169679A1 (en) 2021-09-10
ES3044433T3 (en) 2025-11-26

Similar Documents

Publication Publication Date Title
JP7708772B2 (ja) エストロゲン受容体関連疾患の治療方法
JP7616794B2 (ja) エストロゲン受容体アンタゴニストのレジメン
CN102271681B (zh) Cxcr7调节剂
WO2021197464A1 (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN108366996A (zh) 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物
JP2018517672A (ja) イソオキサゾリル置換イミダゾピリジン類
CN106220644A (zh) 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
JP7557788B2 (ja) 非アルコール性脂肪性肝疾患に対する処置
WO2023093769A1 (en) Aminoheteroaryl kinase inhibitors
EP4469036A2 (en) Compounds and methods for yap/tead modulation and indications therefor
US20250049768A1 (en) Methods of treating estrogen receptor-associated diseases
CN115583938A (zh) 靶向BCL9/β-连环蛋白互相作用的小分子化合物
HK40081119B (en) Compositions for use in a method of treating an estrogen receptor associated cancer
HK40081119A (en) Compositions for use in a method of treating an estrogen receptor associated cancer
WO2023091550A1 (en) Methods of treating estrogen receptor-associated diseases
JP2025521593A (ja) ３βＨＳＤ１阻害剤及び組成物ならびにそれらの使用
WO2024159088A1 (en) Compounds and methods for yap/tead modulation and indications therefor
KR20260040160A (ko) Cyp11a1 억제제로서의 신규 화합물 및 그 용도
CN120583946A (zh) 用于yap/tead调节的化合物和方法及其适应症
WO2014011120A1 (en) Endoperoxides, synthesis and uses thereof for the treatment of neoplastic diseases such as cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250530

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250604

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250703

R150 Certificate of patent or registration of utility model

Ref document number: 7708772

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150